Quick answer: AOD-9604 is an investigational peptide fragment of human growth hormone that was studied for fat loss but failed to deliver. In its largest human trial, it did not produce statistically significant weight loss compared with placebo, and the company developing it dropped it as an obesity drug in 2007. It is not FDA-approved as a medication for fat loss or any condition. Much of what is promoted online about AOD-9604 rests on early-stage or animal data, not solid human results.
This is a neutral overview of an investigational compound. FormBlends works with compounded semaglutide and tirzepatide for weight management.
What is AOD-9604?
AOD-9604 is a synthetic peptide made from a piece of human growth hormone (hGH). Specifically, it corresponds to amino acids 176 to 191 from the tail end of the growth hormone molecule, with a tyrosine added at one end. The idea behind the design was to keep the fat-related activity associated with that region of growth hormone while avoiding the growth-promoting and blood-sugar effects of the full hormone. It was developed by an Australian company, Metabolic Pharmaceuticals, and tested as a potential anti-obesity treatment.
Does AOD-9604 actually work for fat loss?
The honest answer is that the human evidence does not support it. An earlier 12-week study (METAOD005) reported a small average loss of about 2.6 kg on 1 mg daily versus about 0.8 kg on placebo, an encouraging but modest early signal. The larger and more rigorous Phase 2b trial (METAOD006) then failed to reproduce a statistically significant weight loss versus placebo. In other words, in the trial that mattered most, people taking the peptide did not lose meaningfully more weight than people taking a dummy injection. Following that result, development of AOD-9604 as an obesity drug was discontinued in 2007.
Claims of "2 to 4% body fat loss" or specific kilograms of fat lost in men do not match the published human trial outcome. The strongest fat-loss data for AOD-9604 comes from animal and laboratory studies, which do not reliably predict results in people.
How is AOD-9604 supposed to work?
The proposed mechanism is based on preclinical research. In laboratory and animal studies, the fragment appeared to stimulate fat breakdown (lipolysis) and reduce the creation of new fat, while not binding the growth hormone receptor and not affecting blood glucose the way full growth hormone can. This is the theory used to market it. The problem is that an attractive mechanism in cells and animals did not translate into measurable fat loss in the human trial, which is exactly why mechanism alone is not enough to judge a compound.
Optimize your health with expert guidance
Get a personalized treatment plan after licensed provider review. Free consultation included.
Start Free Assessment →What are the claimed benefits for men?
Marketing aimed at men usually promises targeted abdominal and visceral fat loss, preserved muscle, no effect on blood sugar, and few side effects. None of these benefits are established in well-designed human trials specific to men. There is no published, peer-reviewed evidence showing that AOD-9604 produces the body-recomposition results often advertised. Treat male-specific claims with skepticism, because they are not backed by the trial record.
Is AOD-9604 FDA-approved?
No. AOD-9604 is not approved by the FDA as a drug for fat loss or any other use. It received GRAS (generally recognized as safe) status as a food ingredient in 2014, but GRAS food status is not the same as drug approval and says nothing about fat-loss efficacy. Separately, in December 2024 the FDA determined that AOD-9604 should not be added to the 503A Bulks List for pharmacy compounding, citing limited long-term safety data, peptide impurities, and potential immunogenicity. Products sold online as AOD-9604 for fat loss are operating outside the FDA drug-approval framework.
What are the side effects and safety concerns?
Reported side effects in early studies were generally described as mild, but the safety picture is incomplete because the compound never advanced through the full approval process that generates rigorous long-term safety data. When the FDA reviewed AOD-9604 for the 503A compounding list in 2024, it flagged limited long-term safety data, peptide impurities, and possible immunogenicity rather than clearing it. Sourcing is also a real risk: peptides sold through unregulated channels can vary in purity, identity, and sterility, which adds its own hazards independent of the molecule itself.
How does AOD-9604 compare to proven options?
The contrast is stark. The drug class studied in trials like SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide) produced large, statistically significant weight loss in thousands of participants and earned FDA approval. AOD-9604, by comparison, failed its largest human trial and was abandoned as an obesity drug. For someone seeking evidence-based fat loss, the gap between a peptide that failed its trial and medications proven across large trials is the central point.
Frequently asked questions
Does AOD-9604 actually work for weight loss?
The human evidence says no. Its largest Phase 2b trial found no statistically significant weight loss versus placebo, and development as an obesity drug was stopped in 2007.
What is AOD-9604?
A synthetic peptide based on amino acids 176 to 191 of human growth hormone, studied as a potential fat-loss treatment.
Is AOD-9604 FDA-approved?
No. It is not approved as a drug. Its 2014 food-ingredient GRAS status is separate from drug approval, and in 2024 the FDA declined to add it to the 503A compounding list over safety concerns.
What are AOD-9604's benefits for men?
Marketed benefits like targeted belly-fat loss and muscle preservation are not established in well-designed human trials, including in men.
What are the side effects of AOD-9604 in men?
Early studies described mild effects, but long-term safety data are lacking, and unregulated sourcing adds purity and sterility risks.
How does AOD-9604 work?
Preclinical research suggests it stimulates fat breakdown without binding the growth hormone receptor, but this mechanism did not produce fat loss in the human trial.
Where does the "2 to 4% fat loss" claim come from?
Not from the failed human trial. Such figures appear to come from marketing and early or animal data, not from rigorous human results.
Is AOD-9604 better than GLP-1 medications for fat loss?
No. GLP-1 based medications have strong, FDA-reviewed human trial results, while AOD-9604 failed its largest trial.
Related guides
- GHK-Cu for Male Hair Loss: Copper Peptide Evidence
- Peptides for Fat Loss in Men: What the Science Shows
- Fat Loss Peptides for Men: Best Options in 2026
- Peptides vs SARMs for Men: Safety and Effectiveness
- Peptides vs Steroids for Men: Safety Comparison
- Body Recomp Men: Peptides for Muscle & Fat
- Tool: side-effect checker
Sources
- AOD9604. Overview and clinical development history. https://en.wikipedia.org/wiki/AOD9604
- Stier H, et al. Safety and tolerability of AOD9604 (clinical development summary). https://pubmed.ncbi.nlm.nih.gov/21244809/
- FDA. Bulk Drug Substances That Can Be Used to Compound Drug Products (503A Bulks List and review of nominated substances). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- Metabolic Pharmaceuticals (developer and trial history). https://en.wikipedia.org/wiki/Metabolic_Pharmaceuticals
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →